PASG

Passage Bio Inc

PASG, USA

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

https://www.passagebio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PASG
stock
PASG

Passage Bio (PASG) Price Target Increased by 21.85% to 40.39 Nasdaq

Read more →
PASG
stock
PASG

Behavioral Patterns of PASG and Institutional Flows news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$39.6

Analyst Picks

Strong Buy

5

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.02

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-24.90 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.45 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.38

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 46.38% of the total shares of Passage Bio Inc

1.

Orbimed Advisors, LLC

(11.0652%)

since

2025/03/31

2.

Vestal Point Capital LP

(9.5951%)

since

2025/03/31

3.

New Leaf Venture Partners, L.L.C.

(3.9291%)

since

2025/03/31

4.

Erste Asset Management GmbH

(3.8629%)

since

2025/03/31

5.

Vanguard Group Inc

(3.2585%)

since

2025/03/31

6.

TANG CAPITAL MANAGEMENT LLC

(2.3594%)

since

2025/03/31

7.

Vanguard Total Stock Mkt Idx Inv

(2.3038%)

since

2025/07/31

8.

Renaissance Technologies Corp

(2.2183%)

since

2025/03/31

9.

BlackRock Inc

(1.1301%)

since

2025/03/31

10.

Geode Capital Management, LLC

(0.859%)

since

2025/03/31

11.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8049%)

since

2025/07/31

12.

Bridgeway Capital Management, LLC

(0.7961%)

since

2025/03/31

13.

Bridgeway Ultra-Small Company

(0.6544%)

since

2025/06/30

14.

Galileo - Biotech Innovation Fund S USD

(0.6485%)

since

2025/02/28

15.

Fidelity Extended Market Index

(0.4529%)

since

2025/07/31

16.

Fiduciary Trust Co

(0.3382%)

since

2025/03/31

17.

State Street Corp

(0.2466%)

since

2025/03/31

18.

RBF LLC

(0.2246%)

since

2025/03/31

19.

Millennium Management LLC

(0.2143%)

since

2025/03/31

20.

Northern Trust Corp

(0.1761%)

since

2025/03/31

21.

SIMPLEX TRADING, LLC

(0.1295%)

since

2025/03/31

22.

Fidelity Total Market Index

(0.1279%)

since

2025/07/31

23.

Extended Equity Market Fund K

(0.1146%)

since

2025/06/30

24.

Fidelity Series Total Market Index

(0.1119%)

since

2025/07/31

25.

Spartan Extended Market Index Pool F

(0.0955%)

since

2025/07/31

26.

NT Ext Equity Mkt Idx Fd - L

(0.093%)

since

2025/06/30

27.

Northern Trust Extended Eq Market Idx

(0.093%)

since

2025/06/30

28.

NT Ext Equity Mkt Idx Fd - NL

(0.083%)

since

2025/06/30

29.

Two Sigma Investments LLC

(0.0739%)

since

2025/03/31

30.

XTX Topco Ltd

(0.0714%)

since

2025/03/31

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0645%)

since

2025/06/30

32.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0487%)

since

2024/12/31

33.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0262%)

since

2025/06/30

34.

UBS Group AG

(0.0228%)

since

2025/03/31

35.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0222%)

since

2024/12/31

36.

Mariner Wealth Advisors LLC

(0.0188%)

since

2025/03/31

37.

U.S. Equity Market Fund F

(0.0177%)

since

2025/06/30

38.

Extended Equity Market Fund M

(0.0144%)

since

2025/06/30

39.

Diversified Equity Fund F

(0.01%)

since

2025/06/30

40.

SSgA U.S. Total Market Index Strategy

(0.005%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-2.44

EPS Estimate

-0.2

EPS Difference

-2.24

Surprise Percent

-1120%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(1.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.